A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity
Latest Information Update: 26 May 2026
At a glance
- Drugs NNC 06620419 (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 07 May 2026 Planned End Date changed from 1 Dec 2026 to 14 Dec 2026.
- 07 May 2026 Planned primary completion date changed from 1 Dec 2026 to 14 Dec 2026.
- 27 Apr 2026 Status changed from recruiting to active, no longer recruiting.